文献速递疼痛医学

低剂量芬太尼与布比卡因鞘内输注系统更换后复发导管尖端肉芽肿一例

Recurrent intrathecal catheter-tip granuloma formation on a replaced system delivering low dose/concentration fentanyl and bupivacaine: a case report.
PubMed 文献 · Reg Anesth Pain Med · 2025-06-10

本文报道一例50余岁难治性下背痛患者,接受鞘内药物输注治疗,初始使用氢吗啡酮加布比卡因时出现导管尖端肉芽肿,更换系统并改为低剂量芬太尼加布比卡因后5年,在新胸段导管尖端再次出现疑似肉芽肿。结论指出肉芽肿虽不常见但可致严重神经损害,即使采用低剂量方案仍需警惕监测。

要点

  • 鞘内药物输注治疗中导管尖端肉芽肿可复发,即使更换系统和药物方案。
  • 低剂量芬太尼联合布比卡因方案仍可能形成肉芽肿,文献此前未报道。
  • 对鞘内输注患者需定期影像学监测,警惕新发神经症状。

核心结论

  • 导管尖端肉芽肿是鞘内药物输注治疗不常见但可能造成严重损害的并发症,需及时诊断。
  • 即使采用低剂量芬太尼联合布比卡因等降低风险的方案,仍可能发生肉芽肿,需审慎监测。

研究设计与样本

  • 个案报道,描述一例50余岁有多次腰椎手术史和难治性下背痛患者接受鞘内药物输注治疗的临床过程。

主要发现

  • 患者初始接受鞘内氢吗啡酮加布比卡因治疗时出现导管尖端肉芽肿。
  • 更换导管和泵,并将输注药物改为低剂量芬太尼加布比卡因后5年,在新胸段导管尖端发现疑似肉芽肿的新发肿块。
  • 患者出现脊髓病变症状,经生理盐水输注4个月后症状有所改善,随后移除系统。

临床怎么用

  • 对鞘内药物输注治疗患者应定期评估神经症状,必要时行影像学检查以早期发现肉芽肿。
  • 即使使用低剂量阿片类药物方案,也不能放松对导管尖端肉芽肿的监测。

局限性

  • 为单个病例报道,结论外推需谨慎。
  • 复发肉芽肿在文献中仅两次记录,低剂量芬太尼联合布比卡因相关肉芽肿此前未见报道。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrathecal drug delivery (IDD) is a well-established treatment modality for refractory chronic pain. Intrathecal catheter-tip granuloma (ICTG) formation is a known possible complication of opiate IDD and is likely triggered by mast cell degranulation. The use of low concentration and dosage of opioids that do not induce mast cell degranulation has been advised to mitigate the risk of ICTG formation. CASE PRESENTATION: A patient in their 50s with history of multiple lumbar spine surgeries and refractory low back pain who was treated with IDD developed an initial ICTG while receiving intrathecal hydromorphone and bupivacaine. The patient's catheter was thus replaced and repositioned. The pump was also replaced due to repeat motor stall, and the infusate was changed from hydromorphone with bupivacaine to low-dose fentanyl with bupivacaine. Five years later, the patient developed myelopathic symptoms, and on imaging a new mass believed to be an ICTG was detected at the new thoracic catheter tip location. The patient was placed on normal saline infusion for 4 months before system explant, with some improvement of symptoms. CONCLUSIONS: ICTG formation is uncommon but can be a devastating complication of IDD if not properly diagnosed in a timely fashion. Repeat ICTG has only been documented twice in the literature, and ICTG with low dose fentanyl in combination with bupivacaine has not been reported. Despite using regimens and techniques to reduce the risk of ICTG formation, one must judiciously surveil their patients for the dreaded ICTG complication.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Feldheim TV, Hayek SM. Recurrent intrathecal catheter-tip granuloma formation on a replaced system delivering low dose/concentration fentanyl and bupivacaine: a case report. Reg Anesth Pain Med. 2025. PMID: 39581691. doi:10.1136/rapm-2024-105597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。